Roquefort Therapeutics PLC Notice of Admission (6340Z)
September 15 2022 - 7:26AM
UK Regulatory
TIDMROQ
RNS Number : 6340Z
Roquefort Therapeutics PLC
15 September 2022
15 September 2022
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Notice of Admission
Roquefort Therapeutics (LSE:ROQ,OTCQB:ROQAF), the Main Market
listed biotech company focused on developing first in class drugs
in the high value and high growth oncology segment , confirms that
application has been made to the Financial Conduct Authority and
the London Stock Exchange for a total of 57,249,998 new Ordinary
Shares, comprising 50,000,000 Consideration Shares and 7,249,998
Placing Shares of GBP0.01 each, to the Official List of the UKLA by
way of a standard listing under Chapter 14 of the UKLA's Listing
Rules and to trading on the London Stock Exchange's main market for
listed securities ("Admission"). Admission will take place at
8:00a.m. tomorrow.
Completion of the Acquisition and the Placing will become
effective on Admission.
Capitalised terms used in this announcement (unless otherwise
defined) carry the same meanings as those ascribed to them in the
Company's Prospectus dated 13 September 2022, unless the context
requires otherwise.
The Prospectus and further information on the Company can be
found on Roquefort Therapeutic's website at:
https://www.roquefortplc.com
This announcement contains inside information for the purposes
of Article 7 of the UK version of Regulation (EU) No 596/2014 which
is part of UK law by virtue of the European Union (Withdrawal) Act
2018, as amended ("MAR"). Upon the publication of this announcement
via a Regulatory Information Service, this inside information is
now considered to be in the public domain.
-Ends-
Enquiries:
Roquefort Therapeutics plc
+44 (0)20 3290
Stephen West (Chairman) 9339
Hybridan LLP (Joint Broker)
Claire Louise Noyce
Optiva Securities Limited (Joint +44 (0)203 764
Broker) 2341
+44 (0)20 3411
Christian Dennis 1881
Buchanan (Public Relations)
Ben Romney / Jamie Hooper / George +44 (0)20 7466
Beale 5000
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market
listed biotech company developing first in class drugs in the high
value and high growth oncology segment prior to partnering or
selling to big pharma.
Since listing in March 2021, Roquefort Therapeutics has
successfully acquired Lyramid Pty Limited, a leader in the
development of medicines for a new therapeutic target, Midkine (a
human growth factor associated with cancer progression), and most
recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor
Sir Martin Evans, which has developed two families of innovative
cell and RNA oncology medicines.
Roquefort Therapeutics' portfolio consists of four fully funded,
novel patent-protected pre-clinical anti-cancer medicines. The
highly complementary profile of four best-in-class medicines
consists of:
-- Midkine antibodies with significant in vivo efficacy and toxicology studies;
-- Midkine RNA therapeutics with novel anti-cancer gene editing action;
-- MK cell therapy with direct and NK-mediated anti-cancer action; and
-- siRNA targeting novel STAT-6 target in solid tumours showing significant in vivo efficacy.
For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com and @RoquefortTherap on Twitter.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ALSEAFNSFALAEFA
(END) Dow Jones Newswires
September 15, 2022 07:26 ET (11:26 GMT)
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From May 2024 to Jun 2024
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Jun 2023 to Jun 2024